<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>UVA1 phototherapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">UVA1 phototherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">UVA1 phototherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean Krutmann, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Akimichi Morita, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Craig A Elmets, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11512079"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Ultraviolet A1 (UVA1) is a form of phototherapy that uses only the longer, nonerythemogenic ultraviolet (UV) wavelengths (340 to 400 nm), thus reducing the risk of sunburn reactions associated with the shorter wavelength ultraviolet A2 (UVA2; 320 to 340 nm) and ultraviolet B (UVB; 290 to 320 nm). It is important to note that the UVA1 light sources are not equivalent to the light sources used for cosmetic purposes in tanning parlors and home units, which emit UVA2 wavelengths and often some UVB and UVA1. The therapeutic effect of UVA1 is due to its ability to penetrate into the dermis deeper than UVB and target cells that reside in or infiltrate the dermis, including dendritic cells, fibroblasts, mast cells, and T and B lymphocytes [<a href="#rid1">1</a>].</p><p>This topic reviews the mechanism of action, clinical indications, and adverse effects of UVA1 phototherapy. Psoralen plus ultraviolet A (PUVA) photochemotherapy, UVB phototherapy (broadband and narrowband), and targeted phototherapy are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13749.html" rel="external">"Psoralen plus ultraviolet A (PUVA) photochemotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/13752.html" rel="external">"Targeted phototherapy"</a>.)</p><p></p><p class="headingAnchor" id="H11512085"><span class="h1">MECHANISM OF ACTION AND BIOLOGIC EFFECTS</span><span class="headingEndMark"> — </span>Long wavelength ultraviolet A1 (UVA1) radiation (340 to 400 nm) is able to penetrate into the dermis deeper than short wavelength ultraviolet A2 (UVA2; 320 to 340 nm) and ultraviolet B (UVB; 290 to 320 nm). UVA1 exerts its biologic effects on a variety of cells, including T and B lymphocytes, fibroblasts, dendritic cells, and immature mast cells [<a href="#rid2">2-4</a>]. </p><p class="headingAnchor" id="H11512091"><span class="h2">UVA1-induced apoptosis</span><span class="headingEndMark"> — </span>The ability of UVA1 to induce apoptosis of infiltrating T cells is thought to underlie its therapeutic efficacy for the treatment of T cell-mediated inflammatory and neoplastic skin diseases, such as atopic dermatitis and mycosis fungoides. Malignant CD4<sup>+ </sup>T cells appear to be more sensitive to UVA1 radiation-induced apoptosis than normal CD4<sup>+</sup> T cells [<a href="#rid5">5</a>]. </p><p>In vitro, UVA1 has been shown to induce immediate and delayed cell apoptosis through at least two different mechanisms. In the first, UVA1 induces the generation of singlet oxygen species, which depolarize mitochondrial membranes and trigger immediate cell apoptosis through the activation of the FAS/FAS ligand system [<a href="#rid2">2</a>]. This mechanism is termed "preprogrammed cell death" and appears to be specific of UVA1 phototherapy, since it is not observed with UVB or psoralen plus ultraviolet A (PUVA) photochemotherapy. The second mechanism involves the production of superoxide anions, which damage the mitochondrial membrane resulting in the release of cytochrome C and activation of a caspase-dependent apoptotic pathway [<a href="#rid3">3</a>]. </p><p class="headingAnchor" id="H11512097"><span class="h2">Cytokine modulation</span><span class="headingEndMark"> — </span>UVA1 radiation has been shown to suppress proinflammatory cytokines, such as interleukin (IL) 12 and tumor necrosis factor (TNF)-alpha, and downregulate transforming growth factor (TGF)-beta in human skin [<a href="#rid6">6</a>]. In addition, UVA1 decreases the levels of interferon (IFN)-gamma and intercellular adhesion molecule-1 (ICAM-1), which are involved in lymphocyte activation and trafficking. </p><p class="headingAnchor" id="H11512103"><span class="h2">Effects on fibroblasts</span><span class="headingEndMark"> — </span>UVA1-induced singlet oxygen species and hydrogen peroxide upregulate matrix metalloproteinases such as collagenase-1 produced by dermal fibroblasts [<a href="#rid7">7,8</a>]. The resulting increased collagen breakdown is thought to be the mechanism underlying the efficacy of UVA1 in the treatment of morphea and other sclerotic skin diseases [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/16150.html" rel="external">"Morphea (localized scleroderma) in adults: Management", section on 'Phototherapy'</a>.)</p><p class="headingAnchor" id="H2250631015"><span class="h1">LIGHT SOURCES</span><span class="headingEndMark"> — </span>Ultraviolet A1 (UVA1) is generated by fluorescent tubes or filtered metal halide lamps that filter out the erythemogenic ultraviolet A2 (UVA2). Treatment units equipped with fluorescent lamps deliver mean patient irradiance of 20 mW⁄cm<sup>2</sup> and are suitable for low-dose UVA1 [<a href="#rid11">11</a>]. The delivery of medium and high doses of UVA1 requires the higher irradiance (approximately 60 mW⁄cm<sup>2</sup>) of metal-halide units [<a href="#rid11">11</a>]. Because of the high amount of heat generated, metal-halide lamp units require the installation of large fans or other heat-removal systems. Although metal-halide lamps are commonly used as a light source for UVA1 therapy due to their high intensity, they are not efficient because of their broad spectrum (200 to 500 nm) and need of three filters to remove the unnecessary wavelengths.</p><p>Light-emitting diodes (LEDs) are being investigated as an alternative UVA1 light source for UVA1 phototherapy. Preliminary in vitro studies of the wavelength characteristics of aluminium gallium nitride (AlGaN)-based and indium gallium nitride (InGaN)-based LED systems suggest that ultraviolet (UV)-LED devices emitting a peak wavelength of 365 nm may be an effective UVA1 delivery system [<a href="#rid12">12,13</a>].</p><p class="headingAnchor" id="H11512115"><span class="h1">DOSIMETRY</span><span class="headingEndMark"> — </span>Ultraviolet A1 (UVA1) dosimetry is categorized into low (10 to 29 J/cm<sup>2</sup>), medium (30 to 59 J/cm<sup>2</sup>), and high (&gt;60 J/cm<sup>2</sup>) dose regimens. Low-dose UVA1 is generated by fluorescent lamps, whereas medium and high doses require high-intensity emitting metal-halide lamps. (See <a class="local">'Light sources'</a> above.)</p><p>Before initiating treatment, a half-dose of UVA1 is used as a provocation challenge to assess the patient's sensitivity to UVA1. If erythema does not develop, treatment with the required dose of UVA1 can be administered. Treatment times can range from 10 minutes to one hour per treatment session, depending upon the irradiance of the UVA1 phototherapy unit; sessions are typically repeated three to five times per week. In contrast with ultraviolet B (UVB) or psoralen plus ultraviolet A (PUVA) therapies, which use incremental radiation doses, the dose of UVA1 is held constant throughout the treatment.</p><p>The therapeutic efficacy of UVA1 therapy is dose dependent. In studies of patients with atopic dermatitis, a medium UVA1 dose (50 J/cm<sup>2</sup>) was superior to a low-dose UVA1 regimen (10 J/cm<sup>2</sup>), but no significant difference was noted between medium- and high-dose regimens [<a href="#rid14">14,15</a>]. Moreover, low-dose UVA1 (30 J/cm<sup>2</sup>) was less effective than ultraviolet A (UVA)/UVB therapy, whereas high-dose UVA1 therapy (130 J/cm<sup>2</sup>) was superior to UVA/UVB phototherapy [<a href="#rid16">16,17</a>]. </p><p class="headingAnchor" id="H11512121"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Ultraviolet A1 (UVA1) phototherapy was first used for the treatment of atopic dermatitis. In an open study of patients with acute severe exacerbation of atopic dermatitis, high-dose UVA1 (130 J/cm<sup>2</sup>) given daily for 15 consecutive days rapidly induced clinical improvement and reduced the levels of serum eosinophil cationic protein [<a href="#rid17">17</a>]. Subsequently, the indications for UVA1 phototherapy have extended to several other skin diseases, including mycosis fungoides, urticaria pigmentosa, and localized and systemic scleroderma [<a href="#rid18">18</a>].</p><p class="headingAnchor" id="H11512127"><span class="h2">Atopic dermatitis</span><span class="headingEndMark"> — </span>The role of UVA1 phototherapy in the treatment of severe atopic dermatitis is well established:</p><p class="bulletIndent1"><span class="glyph">●</span>A systematic review of nine randomized trials found that in adult patients with acute, severe atopic dermatitis, phototherapy with UVA1 was faster than conventional ultraviolet A (UVA)/ultraviolet B (UVB) in inducing clinical improvement, with a peak response after 10 treatments [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Another systematic review of 19 randomized trials including 905 adult patients with atopic dermatitis showed that medium-dose UVA1 phototherapy was as effective as narrowband ultraviolet B (NBUVB) phototherapy in improving the clinical signs and symptoms of dermatitis as measured with several scoring systems [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2022 systematic review and network meta-analysis of randomized trials evaluating different types of phototherapy for atopic dermatitis found that medium-dose UVA1 cold light was superior to conventional medium-dose UVA1 but similarly effective as high-dose UVA1 [<a href="#rid21">21</a>].</p><p></p><p>The use of UVA1 and other forms of phototherapy for the treatment of severe atopic dermatitis is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/114004.html" rel="external">"Evaluation and management of severe refractory atopic dermatitis (eczema) in adults", section on 'Phototherapy'</a> and  <a class="medical medical_review" href="/z/d/html/1726.html" rel="external">"Management of severe atopic dermatitis (eczema) in children", section on 'Phototherapy'</a>.)</p><p class="headingAnchor" id="H11512133"><span class="h2">Localized scleroderma (morphea)</span><span class="headingEndMark"> — </span>UVA1 has been used for the treatment of morphea (localized scleroderma) and other sclerotic skin diseases [<a href="#rid22">22</a>]. Morphea is characterized by the presence of an inflammatory infiltrate predominantly composed of T helper cells and dysregulated matrix metabolism leading to excessive collagen deposition [<a href="#rid23">23</a>]. Patients with morphea have increased levels of circulating intercellular adhesion molecule-1 (ICAM-1) and fibrogenic T helper 2 (Th2) cytokines, such as interleukin (IL) 4 and transforming growth factor (TGF)-beta. These cytokines recruit eosinophils and other inflammatory cells and induce fibroblasts to synthesize excessive collagen and connective-tissue growth factor. (See  <a class="medical medical_review" href="/z/d/html/13776.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of morphea (localized scleroderma) in adults"</a>.) </p><p>UVA1 irradiation disturbs the cellular responsiveness to TGF-beta-1 through the induction of nonfunctional latent TGF-beta binding protein and the downregulation of TGF-beta receptors. In addition, UVA1 depletes skin-infiltrating T cells by inducing T cell apoptosis; inhibits T cell activation and cytokine production; and upregulates the expression of matrix metalloproteinase-1 (collagenase-1) in dermal fibroblasts [<a href="#rid8">8</a>]. The ultrastructural changes observed in clinically softened skin of scleroderma patients treated with UVA1 include a decrease in the diameter of the broad collagen fibrils in the reticular dermis and de novo synthesis of type I collagen and new thin fibrils [<a href="#rid24">24</a>]. </p><p>Phototherapy for localized scleroderma is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/16150.html" rel="external">"Morphea (localized scleroderma) in adults: Management", section on 'Phototherapy'</a>.) </p><p class="headingAnchor" id="H332462189"><span class="h2">Systemic sclerosis</span><span class="headingEndMark"> — </span>UVA1 may be helpful for the treatment of acral cutaneous sclerosis in patients with systemic sclerosis [<a href="#rid25">25-27</a>]. In a small study of four patients with systemic sclerosis, UVA1 phototherapy induced marked softening of the forearm skin after 9 to 29 exposures, with increase in joint passive range of motion and skin temperature and elasticity [<a href="#rid25">25</a>]. Histologic examination of skin specimens obtained before and after UVA1 phototherapy revealed loosening of collagen bundles and the appearance of small collagen fibers. </p><p class="headingAnchor" id="H11512139"><span class="h2">Urticaria pigmentosa</span><span class="headingEndMark"> — </span>Several studies have suggested that UVA1 phototherapy reduces pruritus and urtication in patients with urticaria pigmentosa. (See  <a class="medical medical_review" href="/z/d/html/103161.html" rel="external">"Mastocytosis (cutaneous and systemic) in children: Epidemiology, clinical manifestations, evaluation, and diagnosis", section on 'Skin'</a> and  <a class="medical medical_review" href="/z/d/html/4784.html" rel="external">"Mastocytosis (cutaneous and systemic) in adults: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Mastocytosis in the skin'</a>.)</p><p>In an open study, four adult patients with severe generalized urticaria pigmentosa were treated with high-dose UVA1 phototherapy administered as monotherapy once daily five times per week for two consecutive weeks [<a href="#rid28">28</a>]. The initial dose of 60 J/cm<sup>2</sup> UVA1 was subsequently increased to 130 J/cm<sup>2</sup> UVA1. High-dose UVA1 therapy reduced pruritus and urtication from stroking (Darier sign) after three exposures, but little or no effect was noted on the hyperpigmented skin lesions. In two patients with systemic manifestations of urticaria pigmentosa, relief from systemic symptoms (eg, migraine, diarrhea) and reduction of elevated serum serotonin to normal levels was observed after 10 exposures. No relapses occurred more than two years after cessation of high-dose UVA1 therapy. </p><p>Another study including 12 patients with urticaria pigmentosa found that high-dose (130 J/cm<sup>2</sup>) and medium-dose (60 J/cm<sup>2</sup>) UVA1 given for 15 days were equally effective in reducing pruritus for six months after the completion of treatment [<a href="#rid29">29</a>]. Although the number of lesions was not reduced after treatment, the number of mast cells in the lesions decreased after treatment and remained low after a follow-up of six months. (See  <a class="medical medical_review" href="/z/d/html/4785.html" rel="external">"Cutaneous mastocytosis: Treatment, monitoring, and prognosis"</a>.)</p><p class="headingAnchor" id="H11512145"><span class="h2">Cutaneous T cell lymphoma</span><span class="headingEndMark"> — </span>In a few small studies, UVA1 phototherapy has been successfully used for the treatment of patients with cutaneous T cell lymphoma [<a href="#rid30">30-33</a>]. In one study, three patients with early-stage mycosis fungoides were treated with high- or medium-dose UVA1 regimen [<a href="#rid30">30</a>]. Complete clinical and histologic clearance of lesions was observed after 16 to 20 exposures. In another study, 11 of 13 patients with widespread plaque-type, nodular, and erythrodermic mycosis fungoides showed complete clinical and histologic response with a high-dose UVA1 regimen [<a href="#rid31">31</a>]. </p><p>Although psoralen plus ultraviolet A (PUVA) photochemotherapy is a widely accepted therapeutic option for early-stage mycosis fungoides, UVA1 phototherapy may be a valuable alternative to PUVA, without the undesirable side effects of oral psoralens (eg, nausea, long-lasting skin photosensitivity, requirement for eye protection). Along the same lines, NBUVB phototherapy is used for the treatment of early stages of mycosis fungoides [<a href="#rid34">34</a>]. (See  <a class="medical medical_review" href="/z/d/html/4757.html" rel="external">"Treatment of early stage (IA to IIA) mycosis fungoides", section on 'Phototherapy'</a>.)</p><p class="headingAnchor" id="H11512151"><span class="h2">Dyshidrotic eczema</span><span class="headingEndMark"> — </span>Localized UVA1 phototherapy appears to be effective for the management of chronic dyshidrotic hand eczema [<a href="#rid35">35-37</a>]. In a small study, 10 of 12 patients with acute exacerbation of dyshidrotic eczema reported a marked improvement after 15 treatments with 40 J/cm<sup>2</sup> per day administered over a period of three weeks [<a href="#rid35">35</a>]. In a small, randomized trial involving 28 patients, medium-dose UVA1 (40 J/cm<sup>2</sup>) was more effective than placebo in improving the symptoms of dyshidrotic eczema as measured by the Dyshidrotic Eczema Area and Severity Index (DASI) score [<a href="#rid36">36</a>]. In a right-left comparison study involving 27 patients, localized high-dose UVA1 (maximum dose 130 J/cm<sup>2</sup>) was as effective as cream PUVA in reducing the DASI score by nearly 50 percent after 15 treatments administered over three weeks [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/13657.html" rel="external">"Acute palmoplantar eczema (dyshidrotic eczema)"</a>.)</p><p class="headingAnchor" id="H11512157"><span class="h2">Other diseases</span><span class="headingEndMark"> — </span>UVA1 phototherapy has also been used for the treatment of a variety of skin conditions, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Pityriasis rubra pilaris [<a href="#rid38">38</a>] (see  <a class="medical medical_review" href="/z/d/html/131425.html" rel="external">"Pityriasis rubra pilaris: Prognosis and management", section on 'Phototherapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypereosinophilic syndromes with cutaneous involvement [<a href="#rid39">39</a>] (see  <a class="medical medical_review" href="/z/d/html/2210.html" rel="external">"Hypereosinophilic syndromes: Treatment"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pityriasis rosea [<a href="#rid40">40</a>] (see  <a class="medical medical_review" href="/z/d/html/5665.html" rel="external">"Pityriasis rosea", section on 'Phototherapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pityriasis lichenoides et varioliformis acuta (PLEVA) and pityriasis lichenoides chronica [<a href="#rid41">41</a>] (see  <a class="medical medical_review" href="/z/d/html/15282.html" rel="external">"Pityriasis lichenoides et varioliformis acuta (PLEVA)", section on 'Phototherapy'</a> and  <a class="medical medical_review" href="/z/d/html/15287.html" rel="external">"Pityriasis lichenoides chronica", section on 'Phototherapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Scleredema [<a href="#rid42">42,43</a>] (see  <a class="medical medical_review" href="/z/d/html/89274.html" rel="external">"Scleredema", section on 'Phototherapy'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary localized cutaneous amyloidosis [<a href="#rid44">44</a>] (see  <a class="medical medical_review" href="/z/d/html/13759.html" rel="external">"Cutaneous manifestations of amyloidosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follicular mucinosis [<a href="#rid45">45</a>] (see  <a class="medical medical_review" href="/z/d/html/1734.html" rel="external">"Approach to the patient with a scalp disorder", section on 'Alopecia mucinosa'</a>)</p><p></p><p class="headingAnchor" id="H11512163"><span class="h1">CONTRAINDICATIONS</span><span class="headingEndMark"> — </span>Ultraviolet A1 (UVA1) phototherapy is contraindicated in patients with the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Xeroderma pigmentosum</p><p class="bulletIndent1"><span class="glyph">●</span>Porphyria</p><p class="bulletIndent1"><span class="glyph">●</span>Melanoma and nonmelanoma skin cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Long-term immunosuppressive therapy (eg, after organ transplantation)</p><p></p><p>Moreover, UVA1 phototherapy should not be used for patients with ultraviolet A (UVA)-sensitive photodermatoses or photosensitive atopic dermatitis or patients taking photosensitizing drugs. The efficacy and long-term safety of UVA1 therapy has not been evaluated and therefore should be used with caution in patients younger than 18 years [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/6622.html" rel="external">"Photosensitivity disorders (photodermatoses): Clinical manifestations, diagnosis, and treatment"</a>.)</p><p class="headingAnchor" id="H11512169"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>Severe acute adverse effects of ultraviolet A1 (UVA1) phototherapy have not been reported. Mild adverse effects are common and include hyperpigmentation, erythema, xerosis, and pruritus. Skin darkening may occur after a single high-dose UVA1 treatment and may limit the efficacy of subsequent UVA1 phototherapy [<a href="#rid47">47</a>]. Although UVA1 is not highly erythemogenic, episodes of phototoxicity may occur, especially among individuals with lightly pigmented skin [<a href="#rid48">48,49</a>].</p><p>Long-term adverse effects of UVA1 phototherapy include photoaging and photocarcinogenesis. Although the carcinogenic potential of UVA1 has not been determined in humans, it is now accepted that UVA1 causes deoxyribonucleic acid (DNA) damage with formation of cyclobutane pyrimidine dimers, which are the most relevant lesions for ultraviolet (UV)-induced mutagenesis [<a href="#rid50">50,51</a>]. </p><p>The actual contribution of ultraviolet A (UVA) radiation to the development of malignant melanoma in humans is still under debate but cannot be excluded. There is a single case report of melanoma in a patient with mastocytosis who received long-term UVA1 and bath psoralen plus ultraviolet A (PUVA) photochemotherapy [<a href="#rid52">52</a>]. Two cases of Merkel cell carcinoma have been reported in immunocompromised patients receiving high-dose UVA1 therapy [<a href="#rid53">53</a>]. </p><p class="headingAnchor" id="H11512175"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Patients receiving ultraviolet A1 (UVA1) phototherapy should be monitored with lifelong regular skin examinations [<a href="#rid46">46</a>]. A complete skin examination for skin cancer, premalignant lesions, and actinic damage should be performed before starting treatment and annually thereafter.</p><p class="headingAnchor" id="H11512181"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Ultraviolet A1 (UVA1) is a form of phototherapy that uses only the longer ultraviolet (UV) wavelengths (340 to 400 nm). The UVA1 therapeutic effect is due to its ability to penetrate into the dermis and target a variety of cells, including T and B lymphocytes, fibroblasts, mast cells, and dendritic cells. (See <a class="local">'Introduction'</a> above and <a class="local">'Mechanism of action and biologic effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Light sources and dosimetry</strong> – UVA1 dosimetry is categorized into low (10 to 29 J/cm<sup>2</sup>), medium (30 to 59 J/cm<sup>2</sup>), and high (&gt;60 J/cm<sup>2</sup>) dose regimens. Low-dose UVA1 is generated by fluorescent lamps, whereas medium and high doses require high-intensity emitting metal-halide lamps. (See <a class="local">'Light sources'</a> above and <a class="local">'Dosimetry'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications for UVA1 phototherapy include severe atopic dermatitis, localized scleroderma, urticaria pigmentosa, and early stage mycosis fungoides. (See <a class="local">'Indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – Short-term adverse effects of UVA1 phototherapy include hyperpigmentation, erythema, xerosis, and pruritus. Long-term adverse effects include photoaging and photocarcinogenesis, although the carcinogenic potential of UVA1 has not been determined. (See <a class="local">'Adverse effects'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol 2010; 49:623.</a></li><li><a class="nounderline abstract_t">Morita A, Werfel T, Stege H, et al. Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy. J Exp Med 1997; 186:1763.</a></li><li><a class="nounderline abstract_t">Godar DE. UVA1 radiation triggers two different final apoptotic pathways. J Invest Dermatol 1999; 112:3.</a></li><li><a class="nounderline abstract_t">Guhl S, Hartmann K, Tapkenhinrichs S, et al. Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells. J Invest Dermatol 2003; 121:837.</a></li><li><a class="nounderline abstract_t">Yamauchi R, Morita A, Yasuda Y, et al. Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis. J Invest Dermatol 2004; 122:477.</a></li><li><a class="nounderline abstract_t">Gambichler T, Skrygan M, Tomi NS, et al. Significant downregulation of transforming growth factor-beta signal transducers in human skin following ultraviolet-A1 irradiation. Br J Dermatol 2007; 156:951.</a></li><li><a class="nounderline abstract_t">Herrmann G, Wlaschek M, Lange TS, et al. UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts. Exp Dermatol 1993; 2:92.</a></li><li><a class="nounderline abstract_t">Yin L, Yamauchi R, Tsuji T, et al. The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol 2003; 30:173.</a></li><li><a class="nounderline abstract_t">Scharffetter K, Wlaschek M, Hogg A, et al. UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo. Arch Dermatol Res 1991; 283:506.</a></li><li><a class="nounderline abstract_t">Gruss C, Reed JA, Altmeyer P, et al. Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. Lancet 1997; 350:1295.</a></li><li><a class="nounderline abstract_t">Kerr AC, Ferguson J, Attili SK, et al. Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol 2012; 37:219.</a></li><li><a class="nounderline abstract_t">Ikumi K, Kio T, Torii K, et al. Successful treatment of dyshidrotic palmoplantar eczema with ultraviolet A1 light-emitting diodes. J Dermatol 2020; 47:922.</a></li><li><a class="nounderline abstract_t">Masuda H, Morita A. Ultraviolet A1 phototherapy utilizing ultraviolet light-emitting diodes and a short wavelength cutoff filter. J Dermatol Sci 2021; 101:138.</a></li><li><a class="nounderline abstract_t">Kowalzick L, Kleinheinz A, Weichenthal M, et al. Low dose versus medium dose UV-A1 treatment in severe atopic eczema. Acta Derm Venereol 1995; 75:43.</a></li><li><a class="nounderline abstract_t">Tzaneva S, Seeber A, Schwaiger M, et al. High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis. J Am Acad Dermatol 2001; 45:503.</a></li><li><a class="nounderline abstract_t">Krutmann J, Diepgen TL, Luger TA, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol 1998; 38:589.</a></li><li><a class="nounderline abstract_t">Krutmann J, Czech W, Diepgen T, et al. High-dose UVA1 therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992; 26:225.</a></li><li><a class="nounderline abstract_t">Tuchinda C, Kerr HA, Taylor CR, et al. UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed 2006; 22:247.</a></li><li><a class="nounderline abstract_t">Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed 2007; 23:106.</a></li><li><a class="nounderline abstract_t">Garritsen FM, Brouwer MW, Limpens J, Spuls PI. Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research. Br J Dermatol 2014; 170:501.</a></li><li><a class="nounderline abstract_t">Xiao H, Gu X, Huang Y, et al. Phototherapy for atopic dermatitis: Systematic review and network meta-analysis of randomized controlled trials. Photodermatol Photoimmunol Photomed 2022; 38:233.</a></li><li><a class="nounderline abstract_t">Kroft EB, Berkhof NJ, van de Kerkhof PC, et al. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol 2008; 59:1017.</a></li><li><a class="nounderline abstract_t">Chizzolini C, Rezzonico R, Ribbens C, et al. Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998; 41:2039.</a></li><li><a class="nounderline abstract_t">Sakakibara N, Sugano S, Morita A. Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis. J Dermatol 2008; 35:63.</a></li><li><a class="nounderline abstract_t">Morita A, Kobayashi K, Isomura I, et al. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol 2000; 43:670.</a></li><li><a class="nounderline abstract_t">Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol 2004; 50:740.</a></li><li><a class="nounderline abstract_t">Rose RF, Turner D, Goodfield MJ, Goulden V. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis. Photodermatol Photoimmunol Photomed 2009; 25:153.</a></li><li><a class="nounderline abstract_t">Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVA1 for urticaria pigmentosa. Lancet 1996; 347:64.</a></li><li><a class="nounderline abstract_t">Gobello T, Mazzanti C, Sordi D, et al. Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study. J Am Acad Dermatol 2003; 49:679.</a></li><li><a class="nounderline abstract_t">Plettenberg H, Stege H, Megahed M, et al. Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1999; 41:47.</a></li><li><a class="nounderline abstract_t">Zane C, Leali C, Airò P, et al. "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001; 44:629.</a></li><li><a class="nounderline abstract_t">Olek-Hrab K, Silny W, Dańczak-Pazdrowska A, et al. Ultraviolet A1 phototherapy for mycosis fungoides. Clin Exp Dermatol 2013; 38:126.</a></li><li><a class="nounderline abstract_t">Rombold S, Lobisch K, Katzer K, et al. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed 2008; 24:19.</a></li><li><a class="nounderline abstract_t">Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135:1377.</a></li><li><a class="nounderline abstract_t">Schmidt T, Abeck D, Boeck K, et al. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol 1998; 78:318.</a></li><li><a class="nounderline abstract_t">Polderman MC, Govaert JC, le Cessie S, Pavel S. A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema. Clin Exp Dermatol 2003; 28:584.</a></li><li><a class="nounderline abstract_t">Petering H, Breuer C, Herbst R, et al. Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol 2004; 50:68.</a></li><li><a class="nounderline abstract_t">Herbst RA, Vogelbruch M, Ehnis A, et al. Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris. Br J Dermatol 2000; 142:574.</a></li><li><a class="nounderline abstract_t">Plötz SG, Abeck D, Seitzer U, et al. UVA1 for hypereosinophilic syndrome. Acta Derm Venereol 2000; 80:221.</a></li><li><a class="nounderline abstract_t">Lim SH, Kim SM, Oh BH, et al. Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea. Ann Dermatol 2009; 21:230.</a></li><li><a class="nounderline abstract_t">Pinton PC, Capezzera R, Zane C, De Panfilis G. Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica. J Am Acad Dermatol 2002; 47:410.</a></li><li><a class="nounderline abstract_t">Thumpimukvatana N, Wongpraparut C, Lim HW. Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy. J Dermatol 2010; 37:1036.</a></li><li><a class="nounderline abstract_t">Demir D, Karaali MG, Kahraman FC, et al. Scleredema of Buschke in a little child and its successful treatment with ultraviolet A1 phototherapy. Turkderm-Turk Arch Dermatol Venereol 2022; 56:186.</a></li><li><a class="nounderline abstract_t">Guillet C, Steinmann S, Maul JT, Kolm I. Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland. Dermatology 2022; 238:579.</a></li><li><a class="nounderline abstract_t">Gil-Villalba A, de la Torre-Gomar FJ, Navarro-Triviño FJ, Ruiz-Villaverde R. Successful treatment of follicular mucinosis with low-dose UVA1 phototherapy. Dermatol Ther 2022; 35:e15773.</a></li><li class="breakAll">Krutmann J, Morita A. Therapeutic photomedicine phototherapy. In: Fitzpatrick's Dermatology in General Medicine, 6th ed, Freedberg IM, Eisen AZ, Wolff K, et al (Eds), McGraw-Hill, 2003. p.2469.</li><li><a class="nounderline abstract_t">Wang F, Garza LA, Cho S, et al. Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. Arch Dermatol 2008; 144:851.</a></li><li><a class="nounderline abstract_t">Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol 2013; 31:438.</a></li><li><a class="nounderline abstract_t">Sterenborg HJ, van der Leun JC. Tumorigenesis by a long wavelength UV-A source. Photochem Photobiol 1990; 51:325.</a></li><li><a class="nounderline abstract_t">Besaratinia A, Synold TW, Chen HH, et al. DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc Natl Acad Sci U S A 2005; 102:10058.</a></li><li><a class="nounderline abstract_t">Tewari A, Grage MM, Harrison GI, et al. UVA1 is skin deep: molecular and clinical implications. Photochem Photobiol Sci 2013; 12:95.</a></li><li><a class="nounderline abstract_t">Wallenfang K, Stadler R. [Association between UVA1 and PUVA bath therapy and development of malignant melanoma]. Hautarzt 2001; 52:705.</a></li><li><a class="nounderline abstract_t">Calzavara-Pinton P, Monari P, Manganoni AM, et al. Merkel cell carcinoma arising in immunosuppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two cases. Photodermatol Photoimmunol Photomed 2010; 26:263.</a></li></ol></div><div id="topicVersionRevision">Topic 91676 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20618465" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : UVA1 phototherapy: a review of mechanism and therapeutic application.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362536" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Evidence that singlet oxygen-induced human T helper cell apoptosis is the basic mechanism of ultraviolet-A radiation phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9886256" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : UVA1 radiation triggers two different final apoptotic pathways.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14632203" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ultraviolet irradiation induces apoptosis in human immature, but not in skin mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009733" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17381457" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Significant downregulation of transforming growth factor-beta signal transducers in human skin following ultraviolet-A1 irradiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156175" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : UVA irradiation stimulates the synthesis of various matrix-metalloproteinases (MMPs) in cultured human fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692352" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1664713" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : UVA irradiation induces collagenase in human dermal fibroblasts in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357412" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22277060" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32441347" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Successful treatment of dyshidrotic palmoplantar eczema with ultraviolet A1 light-emitting diodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33246668" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Ultraviolet A1 phototherapy utilizing ultraviolet light-emitting diodes and a short wavelength cutoff filter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7538257" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Low dose versus medium dose UV-A1 treatment in severe atopic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568738" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : High-dose versus medium-dose UVA1 phototherapy for patients with severe generalized atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9555799" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1552057" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : High-dose UVA1 therapy in the treatment of patients with atopic dermatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16948826" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17598862" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Phototherapy in the management of atopic dermatitis: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24116934" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Photo(chemo)therapy in the management of atopic dermatitis: an updated systematic review with implications for practice and research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34653289" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Phototherapy for atopic dermatitis: Systematic review and network meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18835066" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9811060" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells: different sensitivity to inhibition between systemic sclerosis and control fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18271800" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ultrastructural changes induced in cutaneous collagen by ultraviolet-A1 and psoralen plus ultraviolet A therapy in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11004624" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15097958" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438995" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8531579" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High-dose UVA1 for urticaria pigmentosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512916" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10411410" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ultraviolet A1 (340-400 nm) phototherapy for cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11260537" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23082901" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ultraviolet A1 phototherapy for mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18201353" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of UVA1 phototherapy in 230 patients with various skin diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10566837" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9689317" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14616819" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A double-blind placebo-controlled trial of UVA-1 in the treatment of dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14699368" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of localized high-dose UVA1 irradiation versus topical cream psoralen-UVA for treatment of chronic vesicular dyshidrotic eczema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10777268" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Combined ultraviolet A1 radiation and acitretin therapy as a treatment option for pityriasis rubra pilaris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10954223" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : UVA1 for hypereosinophilic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523795" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Low-dose Ultraviolet A1 Phototherapy for Treating Pityriasis Rosea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12196751" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Medium-dose ultraviolet A1 therapy for pityriasis lichenoides et varioliformis acuta and pityriasis lichenoides chronica.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21083706" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Scleredema diabeticorum successfully treated with ultraviolet A1 phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Scleredema of Buschke in a little child and its successful treatment with ultraviolet A1 phototherapy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34525472" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Primary Localized Cutaneous Amyloidosis: A Retrospective Study of an Uncommon Skin Disease in the Largest Tertiary Care Center in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35976079" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Successful treatment of follicular mucinosis with low-dose UVA1 phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35976079" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Successful treatment of follicular mucinosis with low-dose UVA1 phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18645136" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23806161" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2356228" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Tumorigenesis by a long wavelength UV-A source.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16009942" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23192740" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : UVA1 is skin deep: molecular and clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11544941" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Association between UVA1 and PUVA bath therapy and development of malignant melanoma].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21175855" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Merkel cell carcinoma arising in immunosuppressed patients treated with high-dose ultraviolet A1 (320-400 nm) phototherapy: a report of two cases.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
